Clinical trial · Observational
Cancer-related Venous Thromboembolic Disease - Cohort Study
Establishment of a Patient-based Cohort : Cancer-related Venous Thromboembolic Disease.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Venous thromboembolic disease (VTE) is a common (1/1000), potentially serious disease (10% mortality when the clinical presentation is that of pulmonary embolism (PE)). In cancer patients, the risk of developing VTE is high and constitutes a negative prognostic factor for cancer; the risk of bleeding is also increased. The study of VTE in the context of cancer is a major challenge, given the frequency of the association, the heterogeneity of the situations, the risk factors involved and the therapeutic issues in both curative and primary prevention; in this field, many uncertainties remain, justifying a study focused on the association of VTE and cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Thromboses, Venous | — | UNRESOLVED | — |
| Thrombosis Embolism | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Collection of biological samples | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Cancer patients treated for MVTE
- description
- All the patients are included in one arm. They will undergo various type of samples.
- interventionNames
- Other: Collection of biological samples
Primary outcomes (1)
- measure
- Venous thromboembolic recurrence
- timeFrame
- 5 years
- description
- Venous thromboembolic recurrence
Secondary outcomes (3)
- measure
- Major hemorrhage
- timeFrame
- As long as the patient is on anticoagulant treatment during the 5 years of follow-up
- description
- Fatal haemorrhage, clinical haemorrhage associated with a fall in haemoglobin of 2g/dl or more, clear clinical haemorrhage requiring transfusion of at least 2 red blood cells packed, intracranial, medullary, retroperitoneal, pericardial, intra-articular, intra-muscular, intra-ocular, intra-pulmonary haemorrhage, any other haemorrhage considered serious by the investigator
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged 18 years and more. * Patients with active cancer or requiring cancer treatment at the time of their VTE episode * Patients with documented VTE less than 2 years old * Patients affiliated to the social security system * Patient who has signed a written informed consent Exclusion Criteria: * Patient under 18 * Refusal to participate * Incapacity to consent to the study * Patient under guardianship * Incapacity to communicate (comprehension disorder) * Life expectancy of less than 6 months
References
Publications (0)
Data not yet available